Investors
13.67 RMB
13.67 RMB
| Highest 14.30 |
Lowest 13.62 |
Volume 126149.92 |
Amount 17489 |
| Highest 14.30 |
Lowest 13.62 |
Volume 126149.92 |
Amount 17489 |
Up to 20241029155938 Beijing time. There is 15-minute delay in the quoted price.
[ HitGen H1 2024 Report has Released ]
Up to 20241029155938 Beijing time. There is 15-minute delay in the quoted price.
[ HitGen H1 2024 Report has Released ]
Stock Information
Basic Information
HitGen is a biotech company focused on lead generation and optimization of innovative drug discovery research processes. HitGen has its headquarters based in Chengdu, China. Its core technology is centered around the synthesis and screening of a rapidly expanding and proprietary DNA-encoded compound libraries of novel small and macrocyclic molecules for lead generation.HitGen H1 2023 Report has Released，More details please find (https://www.hitgen.com/en/news-details-311.html).
| HitGen Inc. | |||
| Stock Code | 688222 | Registered Capital | 400,680,000.00 |
| Registered Address | Registered Address Building 1 Floor 3, No.88 South Keyuan Road, Hi-Tech Zone, Chengdu, Sichuan | ||
| Main Business | DNA encoded libraries screening, customized design and synthesis of DNA encoded library, specialized chemistry & bioscience services, and innovative drug discovery project licensing. | ||
| HitGen Inc. | |||
| Stock Code | 688222 | Registered Capital | 400,680,000.00 |
| Registered Address | Registered Address Building 1 Floor 3, No.88 South Keyuan Road, Hi-Tech Zone, Chengdu, Sichuan | ||
| Main Business | DNA encoded libraries screening, customized design and synthesis of DNA encoded library, specialized chemistry & bioscience services, and innovative drug discovery project licensing. | ||
—————— Announcements ——————
临时公告
定期报告
成都先导药物开发股份有限公司2020年年度利润分配预案公告
成都先导2019年年度权益分派实施公告
成都先导关于变更公司注册资本、公司类型、修订《公司章程》并办理工商变更登记的公告
成都先导药物开发股份有限公司关于以集中竞价交易方式回购公司股份的进展公告
德勤华永会计师事务所（特殊普通合伙）关于成都先导药物开发股份有限公司募集资金存放与实际使用情况的专项报告及审核
成都先导药物开发股份有限公司独立董事关于第二届董事会第七次会议相关议案的独立意见
成都先导药物开发股份有限公司2021年限制性股票激励计划预留授予激励对象名单
中国国际金融股份有限公司关于成都先导药物开发股份有限公司首次公开发行股票并在科创板上市的保荐总结报告书
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2023年度持续督导跟踪报告
成都先导药物开发股份有限公司股东询价转让计划书
成都先导药物开发股份有限公司关于召开2024年第三季度业绩说明会的公告
成都先导药物开发股份有限公司2024年第三次临时股东大会
北京君合（成都）律师事务所关于成都先导药物开发股
成都先导药物开发股份有限公司关于获得政府补助的公告
成都先导药物开发股份有限公司关于召开2024年半年度业
The Board Office is in charge of the information disclosure and investor relations. The secretary of the board is Shiwei Geng.
Copyright © 2025 Hitston Ltd.